News

News 12.06.2018 Study should further enhance competitive positioning of MagnetOs Kuros announced that the University Medical Center Utrecht (UMCU) in the Netherlands has obtained approval from its ethical committee to start an investigator-led multicenter study comparing MagnetOs with autologous bone in posterolateral spinal fusion. The study is entitled "A Randomized Controlled Trial of MagnetOs®...

News 30.05.2018 Kuros Biosciences (SIX: KURN) announced the start of an investigator-led study at University Medical Center (UMC) Utrecht, using MagnetOs Granules for maxillary sinus floor elevation with two-stage implant placement. Sinus floor elevation is performed to allow placement of dental implants in the maxilla, or upper jaw. It is most commonly...

News 04.05.2018 Basel, Switzerland, May 04, 2018 / B3C newswire / -- On the occasion of its 20th anniversary, the Swiss Biotech Association launches Swiss Biotech Success Stories in recognition of the industry’s many accomplishments. Swiss Biotech Success Stories will grow over time to encompass all of the industry’s different facets. An...

News 02.05.2018 Kuros Biosciences announced today that it has received the CE Mark for MagnetOs Putty indicated for use as an osteoconductive and osteoinductive bone void filler in the skeletal system (i.e. spine, extremities, pelvis, cranium, mandible and maxilla). This market clearance allows commercialization of MagnetOs Putty in Europe, and complements the...

News 02.05.2018 Biogen (Nasdaq: BIIB) and Neurimmune announced that Biogen has exercised its option to further reduce the previously negotiated royalty rates payable on potential future sales of aducanumab, Biogen’s Phase 3 investigational treatment for early Alzheimer’s disease. Biogen will make a one-time $50 million payment to Neurimmune in exchange for a 5%...